(Press-News.org) Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.
In recent years, several genomic tests have been developed to provide prognostic information for breast cancer. Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, Ireland, and colleagues in the USA examined the agreement in prediction results between two multi-gene assays --the widely used Oncotype DX and a newer PAM50 breast cancer intrinsic classifier.
"At the present time we know there are at least four different breast cancer sub-types with clinical relevance --'luminal A', 'luminal B', 'basal-like' and 'Her2-enriched'. Several commercial assays are being introduced to assign clinical sub-type or predict risk of recurrence for breast cancer," Dr Kelly explained.
"An imminent clinical challenge for practicing physicians is to understand how these different assays relate to each other and what to expect when more than one assay is performed on the same cancer. This is the first study to compare two standardized, readily available but conceptually different prognostic risk predictors."
OncotypeDX is intended for use in patients with hormone receptor-positive, lymph node-negative breast cancer to identify women at low risk of breast cancer recurrence who safely can avoid chemotherapy. It measures the activity of 21 genes and generates a recurrence score (RS) which categorizes patients into low, intermediate or high risk groups depending on the risk of distant recurrence.
The PAM50 breast cancer intrinsic classifier measures the expression of 50 genes and stratifies breast cancers into five sub-types; luminal A, luminal B, basal-like, Her2-enriched and normal-like, so the target population is not just patients with ER-positive breast cancers. This test is currently undergoing clinical validation.
The researchers assessed the two tests on 119 breast cancer specimens from patients who the researchers classified as being at 'clinically intermediate' risk for recurrence based on several criteria: median tumor size 1.5cm, all estrogen receptor-positive, Her2 negative, lymph-node negative and most grade II.
"In other words, these patients would likely be a challenge in terms of whether they would benefit from chemotherapy or not," Dr Kelly said. "In these situations, multi-gene assays can provide additional independent prognostic information."
The results showed that all patients with high RS according to the OncotypeDX were classified as 'luminal B' or 'basal-like' by the PAM50 classifier, whereas the majority of low RS cases (83%) were "luminal A" type. Half (51%) of the Intermediate RS cancers were re-categorized as low risk 'luminal A' cancers by the PAM50. All 'luminal A' cancers are either Low (70%) or Intermediate (30%) risk by RS, whereas 'luminal B' cancers are comprised of a mixed risk group by RS including 33% that are high risk by OncotypeDX.
"These results indicate that there is reasonably good agreement between the two methods for high and low prognostic risk assignment," Dr Kelly said. "However, intermediate risk groups by one assay often include cases with discordant risk prediction by the other method. When discordant risk results are obtained it is currently unknown which assay will predict outcome more accurately."
"At the present time it is uncertain whether patients with an intermediate OncotypeDx RS benefit from chemotherapy," Dr Kelly added. "It is interesting that PAM50 re-categorized about half of the patients with intermediate RS to the low risk luminal A category which suggests that these patients may not benefit much from adjuvant chemotherapy due to their already very good prognosis and limited chemotherapy sensitivity."
However, she noted, PAM50 is currently undergoing validation. "We will have to wait for outcome data to see which test is most accurate at predicting outcome particularly."
Commenting on this study, which he was not involved in, Prof Roberto Labianca, from Ospedali Riuniti di Bergamo, Italy, noted that the data with PAM50 are very interesting, because they indicate that in the 'intermediate risk' group (as defined by the well-established method OncotypeDX) it could be possible to exclude additional patients from adjuvant chemotherapy.
"However, a validation of these findings in a larger population is mandatory before they can be translated into clinical practice."
INFORMATION: END
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies.
At the IMPAKT Breast Cancer Conference in Brussels, Dr Gargi Patel from the Richard Dimbleby Department, King's College London, described cutting-edge research in which she and colleagues captured detailed information about protein interactions on cancer cells, and correlated that with established genetic markers for cancer ...
The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.
The results of a randomized trial in 45 patients with primary invasive breast cancer showed that the drug --which is currently used to treat arthritis and other painful conditions-- clearly induced an anti-tumor response at the molecular level.
"This is exciting because it means that a medication already used to treat other diseases may be efficient in the adjuvant treatment of breast cancer ...
Domenico Di Ceglie, Director of Training and Research at the Gender Identity Development Service at the Tavistock and Portman NHS Foundation Trust in London, commented: "These are important findings in the field of gender incongruence, which need to be replicated. The awareness of the presence of autistic features may help these young people to explore the reasons behind their perceptions, and help them make more informed decisions about treatment."
Emma Martin, who runs a Gender Identity Support and research group in Little Downham, UK, welcomed the new findings, and ...
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
The biosensor has been developed by researchers at the Virginia Institute of Marine Science (VIMS) and was tested in the Elizabeth River and Yorktown Creek which both drain into Virginia's Chesapeake Bay.
"Our biosensor combines the power of the immune system ...
Spine Surgeon LA, the leading spine surgery specialists in the state of California has recently launched their website at the URL www.spinesurgeonla.com
Spine Surgeon LA is a medical hub wherein they treat and address several different types of spine problems. These spine problems include: Bulging Disc, Herniated Disc, Spine Scoliosis, Pinched Nerve, Spine Stenosis, Bone Spurs, and Spine Tumors among others. In their new website, spinesurgeonla.com, you may click on these common spine problems and then get a chance to read some information about them so that you may ...
Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.
University of Manchester researchers, working with colleagues in Newark, USA, have developed a new test that can not only better diagnose Aspergillus infection, but can also spot signs of antifungal resistance to azoles – the class of drugs used to treat patients with aspergillosis.
Using the new test, which uses direct molecular detection rather than culturing the fungus in a Petri dish, the ...
The recent nuclear accident in Fukushima Daiichi in Japan has brought the nuclear debate to the forefront of controversy. While Japan is trying to avert further disaster, many nations are reconsidering the future of nuclear power in their regions. A study by Behnam Taebi from the Delft University of Technology, published online in the Springer journal Philosophy & Technology, reflects on the various possible nuclear power production methods from an ethical perspective: If we intend to continue with nuclear power production, which technology is most morally desirable?
On ...
(WASHINGTON) -- Researchers in the Materials Science and Technology division of the Naval Research Laboratory have recently demonstrated electrical injection, detection and precession of spin accumulation in silicon, the cornerstone material of modern device technology, at temperatures up to 225 degrees Celsius. These results provide the first demonstration that spin accumulation in Si is viable as a basis for practical devices which meet the operating temperatures specified for commercial (85˚C), industrial (100˚C) and military (125˚C) applications. This ...
Pan American Metals of Miami (PAMOM), continues to provide opportunities for investment in the bullion markets. "Precious metals are tried and tested and provide investors with a safe alternative to low interest rates and decreasing currency values," says Bill Hionas, CEO of PAMOM.
PAMOM deals in four precious metals; silver, gold, platinum and palladium. The current market is showing dips in all precious metal prices, providing savvy investors with a perfect opportunity to buy.
"Long-term predictions remain optimistic for the precious metals market, ...
Scientists have discovered why some people may be protected from harmful parasitic worms naturally while others cannot in what could lead to new therapies for up to one billion people worldwide.
Parasitic worms are a major cause of mortality and morbidity affecting up to a billion people, particularly in the Third World, as well as domestic pets and livestock across the globe.
Now, University of Manchester researchers have, for the first time, identified a key component of mucus found in the guts of humans and animals that is toxic to worms.
"These parasitic worms ...
